Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HPGDS | O60760 | 1/20 | 0.53 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18397939 | 0.98 | GAA (0.57) | GAAHPGDSALKBH2NPC1RAB9A | |
| SCHEMBL6733486 | 0.84 | GAA (0.41) | GAAHPGDSALKBH2NPC1RAB9A | |
| SCHEMBL9952472 | 0.81 | MEN1 (0.42) | GAAHPGDSALKBH2SMN1; SMN2GRM4 | |
| SCHEMBL2121774 | 0.80 | CYP2A6 (0.53) | GAAGRM4HTT | |
| Acetamide SCHEMBL28142841 | 0.80 | HPGDS (0.48) | GAAHPGDSALKBH2NPC1RAB9A | |
| SCHEMBL15779430 | 0.79 | MAPT (0.50) | GAANPC1RAB9AGRM4DRD2 | |
| SCHEMBL17095020 | 0.79 | MAP4K4 (0.50) | NPC1RAB9ADRD2DRD4DRD3 | |
| SCHEMBL15006906 | 0.79 | MAPT (0.44) | GAANPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL30660600 | 0.79 | GAA (0.37) | GAAHPGDSALKBH2NPC1RAB9A | |
| SCHEMBL2132953 | 0.77 | NOTUM (0.47) | GAANPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-1284559-A | — | — | None | — | — | JP | disclosed |
| EP-4735430-A1 | MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2026-05-06 | — | — | EP | disclosed |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4637738-A2 | INHIBITORS OF JAK2 | Llydaw Therapeutics, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250214948-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2025-07-03 | — | — | US | disclosed |
| US-20250145642-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | Kineta, Inc. | 2025-05-08 | — | — | US | disclosed |
| WO-2025038863-A1 | INDOLE AND PYRROLOYPYRIDINE DERIVATIVES AS GPR17 MODULATORS | BIOGEN MA INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| WO-2025003414-A1 | MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-02 | — | — | WO | disclosed |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-11-14 | — | — | US | disclosed |
| US-7157472-B2 | Neuropeptide Y Y5 receptor antagonists | SCHERING CORPORATION (US) | 2007-01-02 | — | — | US | disclosed |
| CN-1875144-A | Reactive colouring of leather | BASF AG (DE) | 2006-12-06 | — | — | CN | disclosed |
| EP-1682717-A1 | METHOD FOR THE REACTIVE COLOURING OF LEATHER | BASF Aktiengesellschaft (DE) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005121439-A1 | METHOD FOR THE REACTIVE COLORATION OF LEATHER | BASF AKTIENGESELLSCHAFT (DE) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005040490-A1 | METHOD FOR THE REACTIVE COLOURING OF LEATHER | BASF AKTIENGESELLSCHAFT (DE) | 2005-05-06 | — | — | WO | disclosed |
| CN-1066448-C | Amide derivatives | OTSUKA PHARMA CO LTD (JP) | 2001-05-30 | — | — | CN | disclosed |
| CN-1221419-A | Amide derivatives | OTSUKA PHARMA CO LTD (JP) | 1999-06-30 | — | — | CN | disclosed |
| JP-H01284559-A | AROMATIC HETEROCYCLIC AZO DYES | CIBA GEIGY AG | 1989-11-15 | — | — | JP | disclosed |
| US-4108982-A | DIURETICS, HYPOTENSIVE AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1978-08-22 | — | — | US | disclosed |
| US-4066638-A | WATER-SOLUBLE FIBER REACTIVE PHENYL-AZO-NAPHTHYL DYESTUFFS CONTAINING TWO SULFO GROUPS IN THE PHENYL MOIETY | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | GAA 4402/4885HPGDS 3400/4885ALKBH2 834/4885 |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | GAA 3048/4885HPGDS 2782/4885ALKBH2 1121/4885 |
| US-20250214948-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | NTRK2, BDNF, NGF | GAA 2905/4885HPGDS 2700/4885ALKBH2 4528/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | GAA 3048/4885HPGDS 2782/4885ALKBH2 1121/4885 |
| US-20250145642-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | TARDBP, TDP2, PSEN2 | GAA 441/4885HPGDS 4142/4885ALKBH2 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.